Clinical Trial Update: A Phase 2 Trial of Fluzoparib Combined With Apatinib Versus Fluzoparib Monotherapy in Treatment With Relapsed Ovarian Cancer Patients [Phase 2]

View source ↗

Summary

A Phase 2 trial evaluating Fluzoparib in combination with Apatinib versus Fluzoparib alone in relapsed ovarian cancer has completed.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Ovarian Cancer

Drugs mentioned

• Apatinib (apatinib)
• Fluzoparib (fluzoparib)

Snippet

Sponsor: Jiangsu HengRui Medicine Co., Ltd. | Conditions: Relapsed Ovarian Cancer | Phase 2 | Status: COMPLETED